Why the study?
Does pimobendan improve clinical scores and survival compared to benazepril in dogs with acquired atrioventricular valvular disease?
Does pimobendan improve clinical scores and survival compared to benazepril in dogs with acquired atrioventricular valvular disease?
Pimobendan significantly improves clinical scores and prolongs survival compared to benazepril in dogs with acquired atrioventricular valvular disease.
Answers are grounded in this paper and cite their sources.
Supports preferential pimobendan use over benazepril; extends RCT evidence for survival benefit in canine AV valvular disease.
Seventy-six dogs with clinical acquired atrioventricular valvular disease were evaluated to determine the efficacy of pimobendan (n=41) versus benazepril hydrochloride (n=35) in a randomized, positive-controlled, multicenter study. The study was divided into 56-day and long-term evaluation periods. In a subgroup of dogs with concurrent furosemide treatment (pimobendan [n=31], benazepril [n=25]), the Heart Insufficiency Score improved in favor of pimobendan (P=0.0011), equating to a superior overall efficacy rating (P<0.0001) at day 56. Long-term median survival (i.e., death or treatment failure) for dogs receiving pimobendan was 415 days versus 128 days for dogs not on pimobendan (P=0.0022).
No takes yet. Share an insight, caveat, or question.
Lombard et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: